Cao Feng, Jia Jinghao, Yin Zhi, Gao Yahan, Sha Lei, Lai Yisheng, Ping Qineng, Zhang Yihua
Department of Pharmaceutics and §Center of Drug Discovery, School of Pharmacy, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing 210009, P. R. China.
Mol Pharm. 2012 Aug 6;9(8):2127-35. doi: 10.1021/mp200447r. Epub 2012 Mar 9.
The purposes of this study were to expand the structure of parent drugs selected for peptide transporter 1 (PepT1)-targeted ester prodrug design and to improve oral bioavailability of oleanolic acid (OA), a Biopharmaceutics Classification System (BCS) class IV drug. Through an ethoxy linker the carboxylic acid group of OA was conjugated with the carboxylic acid group of different amino acid promoieties to form six diester prodrugs. The effective permeability (P(eff)) of prodrugs was screened by in situ rat single-pass intestinal perfusion (SPIP) model in two buffers with different pH (6.0 and 7.4) as PepT1 employs a proton-gradient as the driving force. Compared to OA, 2.5-fold, 2.3-fold, 2.2-fold, 2.1-fold, and 1.9-fold enhancement of P(eff) in buffer with pH 6.0 was observed for L-Phe ester (5c), L-Val ester (5a), L-Lys ester (5e), D-Phe ester (5d), and D-Val ester (5b), respectively. Furthermore, P(eff) of 5a, 5c, 5d and 5e in pH 6.0 was significantly higher than that in pH 7.4 (p < 0.01), respectively. These results showed that the H(+) concentration of perfusion solution had great effect on the transport of the prodrugs across intestinal membrane. For the further evaluation of affinity to PepT1, inhibition studies were performed by coperfusing 0.1 mM prodrug with 50 mM glycyl-sarcosine (Gly-Sar, a typical substrate of PepT1). It turned out that the P(eff) of 5a, 5b, 5c and L-Tyr ester (6f) significantly reduced in the presence of Gly-Sar (1.7-fold, 2.2-fold, 1.9-fold, and 1.4-fold, respectively). We supposed that it may be attributed to PepT1 mediated transport of these prodrugs. 5a and 6f were selected as the optimal target prodrugs for oral absorption in vivo. Following intragastric administration of 300 mg/kg (calculated as OA) 5a, 6f and OA in three groups of rats, compared with group OA, Cmax for the group of 5a and 6f was enhanced by 1.56-fold and 1.54-fold, respectively. Fapp of group 5a and 6f was 2.21- and 2.04-fold increased, respectively, indicating that 5a and 6f had better oral absorption than OA. The combined results also suggest that diester prodrugs which conjugated two carboxylic acid groups of proper amino acid promoieties and parent drug through a linker can be used for PepT1-targeted prodrug design. With this strategy, oral bioavailability of OA in rats could be improved significantly.
本研究的目的是扩展用于肽转运体1(PepT1)靶向酯前药设计的母体药物结构,并提高齐墩果酸(OA)的口服生物利用度,OA是一种生物药剂学分类系统(BCS)IV类药物。通过乙氧基连接子,OA的羧酸基团与不同氨基酸部分的羧酸基团共轭,形成六种二酯前药。前药的有效渗透率(P(eff))通过原位大鼠单通道肠道灌注(SPIP)模型在两种不同pH值(6.0和7.4)的缓冲液中进行筛选,因为PepT1利用质子梯度作为驱动力。与OA相比,在pH 6.0的缓冲液中,L-苯丙氨酸酯(5c)、L-缬氨酸酯(5a)、L-赖氨酸酯(5e)、D-苯丙氨酸酯(5d)和D-缬氨酸酯(5b)的P(eff)分别提高了2.5倍、2.3倍、2.2倍、2.1倍和1.9倍。此外,5a、5c、5d和5e在pH 6.0时的P(eff)分别显著高于pH 7.4时的P(eff)(p < 0.01)。这些结果表明,灌注溶液的H(+)浓度对前药跨肠膜转运有很大影响。为了进一步评估对PepT1的亲和力,通过将0.1 mM前药与50 mM甘氨酰-肌氨酸(Gly-Sar,PepT1的典型底物)共同灌注进行抑制研究。结果表明,在存在Gly-Sar的情况下,5a、5b、5c和L-酪氨酸酯(6f)的P(eff)显著降低(分别为1.7倍、2.2倍、1.9倍和1.4倍)。我们推测这可能归因于PepT1介导的这些前药的转运。5a和6f被选为体内口服吸收的最佳靶向前药。在三组大鼠中分别胃内给予300 mg/kg(以OA计算)的5a、6f和OA后,与OA组相比,5a组和6f组的Cmax分别提高了1.56倍和1.54倍。5a组和6f组的Fapp分别增加了2.21倍和2.04倍,表明5a和6f比OA具有更好的口服吸收。综合结果还表明,通过连接子将适当氨基酸部分的两个羧酸基团与母体药物共轭的二酯前药可用于PepT1靶向前药设计。采用这种策略,大鼠体内OA的口服生物利用度可显著提高。